Data instanted at the San Antonio B...

Data instanted at the San Antonio Breast Cancer Symposium present to view the effect of Arimidex (anastrozole, AstraZeneca, Wilmington, DE) as an adjuvant treatment in postmenopausal women with early breast cancer. After a median of 333 month follow-up and a median duration of treatment of 307 month 317 of 3125 women in the meditation drug group had a relapse of their breast cancer or died, compared with 379 of 3116 women in the tamoxifen collection This represents a 17% reduction in the risk of return with the investigational treatment. The reduction was 22% in women with confirmed